Skip to main content

Table 1 Correlation between NTRS group and clinicopathological factors of glioma patients in the two cohorts

From: A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients

Features Training set TCGA RNA-seq cohort (n = 660) Validation set CGGA RNA-seq cohort (n = 668)
NTRSLow(n = 391) NTRSHigh(n = 269) p-value NTRSLow(n = 281) NTRSHigh(n = 387) p-value
Age
 Mean (range) 41 (17–75) 56 (14–89) < 0.001*** 41 (12–69) 45 (11–76) < 0.001***
Gender
 Female 170 108 0.38 135 153 < 0.05*
 Male 219 161   146 234  
 NA 2 0     
WHO Grade
 II 224 19 < 0.001*** 106 74 < 0.001***
 III 163 96   136 115  
 IV 3 154   39 198  
 NA 1 0     
IDH status
 Wildtype 12 221 < 0.001*** 44 233 < 0.001***
 Mutant 373 43   228 115  
 NA 6 5   9 39  
Chr.1p/19q status
 Noncodeletion 223 249 < 0.001*** 162 299 < 0.001***
 Codeletion 163 3   117 24  
 NA 5 17   2 64  
Histology
 Astrocytoma 120 71 < 0.001*** 57 67 < 0.001***
 Oligodendroglioma 168 17   52 29  
 Oligoastrocytoma 100 27   133 93  
 Glioblastoma 3 154   39 198  
MGMT promoter status
 Methylated 352 111 < 0.001*** / /  
 Unmethylated 30 123   / /  
 NA 9 35   / /  
Chr.7.gain&Chr.10.loss
 Yes 1 146 < 0.001*** / /  
 No 380 106   / /  
 NA 10 17   / /  
Chr.19&20 gain
 Non-gain 381 222 < 0.001*** / /  
 Gain 0 30   / /  
 NA 10 17   / /  
ATRX status
 Wildtype 227 218 < 0.001*** / /  
 Mutant 155 33   / /  
 NA 9 18   / /  
  1. P < 0.05 (*), P < 0.01 (**) and P < 0.001 (***) is regarded as statistically significant
  2. NA not applicable
\